Yang Quanhe, Rasmussen Sonja A, Friedman J M
National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, 4770 Buford Highway, MS F-45, Atlanta, GA 30341, USA.
Lancet. 2002 Mar 23;359(9311):1019-25. doi: 10.1016/s0140-6736(02)08092-3.
Down's syndrome is the most frequently identified cause of mental retardation, but information about mortality and comorbidity in people with Down's syndrome is limited.
We used data from US death certificates from 1983 to 1997 to calculate median age at death and standardised mortality odds ratios (SMORs) for common medical disorders in people with Down's syndrome.
Of 17897 people reported to have Down's syndrome, median age at death increased from 25 years in 1983 to 49 years in 1997, an average increase of 1.7 years per year studied (p<0.0001). Median age at death was significantly lower in black people and people of other races than in white people with Down's syndrome. As expected, death certificates with a diagnosis of Down's syndrome were more likely to list congenital heart defects (SMOR 29.1, 95% CI 27.8-30.4), dementia (21.2, 19.6-22.7), hypothyroidism (20.3, 18.5-22.3), or leukaemia (1.6, 1.4-1.8) than were those that did not report Down's syndrome. By contrast, malignant neoplasms other than leukaemia were listed on death certificates of people with Down's syndrome less than one-tenth as often as expected (0.07, 0.06-0.08). A strikingly low SMOR for malignancy was associated with Down's syndrome at all ages, in both sexes, and for all common tumour types except leukaemia and testicular cancer.
Identification of factors responsible for the racial differences recorded could facilitate further improvement in survival of people with Down's syndrome. Reduced exposure to environmental factors that contribute to cancer risk, tumour-suppressor genes on chromosome 21, or a slower rate of replication or higher likelihood of apoptosis in Down's syndrome cells, could be possible reasons for paucity of cancer in people with Down's syndrome.
唐氏综合征是最常见的智力发育迟缓病因,但关于唐氏综合征患者死亡率及合并症的信息有限。
我们利用1983年至1997年美国死亡证明的数据,计算唐氏综合征患者的死亡年龄中位数以及常见医学病症的标准化死亡比值比(SMORs)。
在报告患有唐氏综合征的17897人中,死亡年龄中位数从1983年的25岁增至1997年的49岁,在所研究的年份中平均每年增加1.7岁(p<0.0001)。患有唐氏综合征的黑人及其他种族人群的死亡年龄中位数显著低于白人。正如预期的那样,诊断为唐氏综合征的死亡证明比未报告唐氏综合征的死亡证明更有可能列出先天性心脏缺陷(SMOR 29.1,95%可信区间27.8 - 30.4)、痴呆(21.2,19.6 - 22.7)、甲状腺功能减退(20.3,18.5 - 22.3)或白血病(1.6,1.4 - 1.8)。相比之下,除白血病外的恶性肿瘤在唐氏综合征患者的死亡证明上列出的频率比预期低十分之一以上(0.07,0.06 - 0.08)。在所有年龄、男女以及除白血病和睾丸癌外的所有常见肿瘤类型中,唐氏综合征与显著较低的恶性肿瘤SMOR相关。
确定造成所记录种族差异的因素有助于进一步提高唐氏综合征患者的生存率。接触导致癌症风险的环境因素减少、21号染色体上的肿瘤抑制基因、唐氏综合征细胞中复制速度较慢或凋亡可能性较高,可能是唐氏综合征患者癌症较少的原因。